AUTOLUS THERAPEUTICS PLC - AMERICAN DEPOSITARY SHA

Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026

12 1 2026 07:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform

06 1 2026 09:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025

08 12 2025 16:05:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025

08 12 2025 08:35:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Appoints Ryan Richardson to Board of Directors

01 12 2025 07:00:00 提供 Nasdaq GlobeNewswire

NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹

25 11 2025 04:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

13 11 2025 16:05:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

12 11 2025 07:00:01 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

03 11 2025 09:05:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

30 10 2025 07:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

27 10 2025 07:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis

20 10 2025 07:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

15 10 2025 16:05:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025

16 9 2025 08:05:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

12 8 2025 07:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

24 7 2025 07:30:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

21 7 2025 07:00:31 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

15 7 2025 16:05:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

12 6 2025 02:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Participate in Upcoming Investor Conferences

29 5 2025 16:05:00 提供 Nasdaq GlobeNewswire